Skip to content

Eptifibatide

    Brands

    DEA Class; Rx

    Common Brand Names; Integrilin

    • Antiplatelet Agents, Cardiovascular; 
    • Glycoprotein IIb/IIIa Inhibitors

    Intravenous platelet aggregation, glycoprotein IIb/IIIa inhibitor
    Used for the treatment of patients undergoing percutaneous coronary intervention (PCI) and acute coronary syndromes managed medically or with PCI
    Associated with bleeding and hypotension

    Indicated for the adjunctive treatment of patients undergoing percutaneous coronary intervention (PCI), including those undergoing coronary stenting, to prevent cardiac ischemic complications (e.g., myocardial infarction prophylaxis).

    For the treatment of patients with acute coronary syndrome (unstable angina or acute myocardial infarction, NSTEMI), including patients who are to be managed medically, and for those undergoing percutaneous coronary intervention (PCI).
    For the treatment of patients with acute myocardial infarction, STEMI undergoing percutaneous coronary intervention (PCI).

    Hypersensitivity

    History of internal bleeding, intracranial hemorrhage or neoplasm, CVA, thrombocytopenia

    AV malformation or aneurysm, aortic dissection, severe HTN, acute pericarditis

    Other parenteral glycoprotein IIb/IIIa inhibitors

    • Bleeding (8%)
    • Hypotension (7%)
    • Thrombocytopenia (2.3%)
    • Injection site reaction
    • Hypersensitivity
    • Intracranial hemorrhage
    • Pulmonary hemorrhage
    • Thrombocytopenia
    • GI hemorrhage
    • Immune-mediated thrombocytopenia (thought to be caused by antibodies that react with GP IIb/IIIa complex)

    —

    Available data on use in pregnant women from published literature and pharmacovigilance database are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes

    Untreated myocardial infarction can be fatal to pregnant woman and fetus

    There are no available data on presence of drug in human milk, effects on breastfed infant, or on milk production; as drug is a peptide, it is likely to be destroyed in infant’s gastrointestinal tract and not absorbed orally by the breastfed infant

    Adults

    180 mcg/kg (Max: 22.6 mg) IV bolus and 2 mcg/kg/minute (Max: 15 mg/hour) continuous IV infusion.

    Geriatric

    180 mcg/kg (Max: 22.6 mg) IV bolus and 2 mcg/kg/minute (Max: 15 mg/hour) continuous IV infusion.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Eptifibatide

    injection solution

    • 2mg/mL
    • 0.75mg/mL